Share-based Payment Arrangement, Expense of Marker Therapeutics, Inc. from 30 Sep 2015 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Marker Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Sep 2015 to 30 Sep 2025.
  • Marker Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $33,000, a 38% decline year-over-year.
  • Marker Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $477,000, a 42% increase year-over-year.
  • Marker Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $246,000, a 84% decline from 2023.
  • Marker Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $1,583,000, a 70% decline from 2022.
  • Marker Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $5,344,000, a 10% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Marker Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $477,000 $33,000 -$20,000 -38% 01 Jul 2025 30 Sep 2025 10-Q 13 Nov 2025 2025 Q3
Q2 2025 $497,000 $14,000 -$49,000 -78% 01 Apr 2025 30 Jun 2025 10-Q 14 Aug 2025 2025 Q2
Q1 2025 $546,000 $379,000 +$300,000 +380% 01 Jan 2025 31 Mar 2025 10-Q 15 May 2025 2025 Q1
Q4 2024 $246,000 $51,000 -$91,000 -64% 01 Oct 2024 31 Dec 2024 10-K 31 Mar 2025 2024 FY
Q3 2024 $337,000 $53,000 -$122,000 -70% 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2025 2025 Q3
Q2 2024 $459,000 $63,000 -$543,000 -90% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025 2025 Q2
Q1 2024 $1,002,000 $79,000 -$581,000 -88% 01 Jan 2024 31 Mar 2024 10-Q 15 May 2025 2025 Q1
Q4 2023 $1,583,000 $142,000 -$573,000 -80% 01 Oct 2023 31 Dec 2023 10-K 31 Mar 2025 2024 FY
Q3 2023 $2,156,000 $175,000 -$1,321,000 -88% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024 2024 Q3
Q2 2023 $3,477,000 $606,000 -$896,000 -60% 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2024 2024 Q2
Q1 2023 $4,373,000 $660,000 -$971,000 -60% 01 Jan 2023 31 Mar 2023 10-Q 15 May 2024 2024 Q1
Q4 2022 $5,344,000 $715,000 -$752,000 -51% 01 Oct 2022 31 Dec 2022 10-K 26 Mar 2024 2023 FY
Q3 2022 $6,096,000 $1,496,000 +$28,000 +1.9% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $6,068,000 $1,502,000 -$150,000 -9.1% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023 2023 Q2
Q1 2022 $6,218,000 $1,631,000 +$254,000 +18% 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023 2023 Q1
Q4 2021 $5,964,000 $1,467,000 01 Oct 2021 31 Dec 2021 10-K 22 Mar 2023 2022 FY
Q3 2021 $1,468,000 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q2 2021 $1,652,000 01 Apr 2021 30 Jun 2021 10-Q 11 Aug 2022 2022 Q2
Q1 2021 $1,377,000 01 Jan 2021 31 Mar 2021 10-Q 13 May 2022 2022 Q1
Q3 2016 $573,137 +$559,893 +4228% 01 Jul 2016 30 Sep 2016 10-Q 04 Nov 2016 2016 Q3
Q3 2015 $13,244 01 Jul 2015 30 Sep 2015 10-Q 04 Nov 2016 2016 Q3

Marker Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $246,000 -$1,337,000 -84% 01 Jan 2024 31 Dec 2024 10-K 31 Mar 2025 2024 FY
2023 $1,583,000 -$3,761,000 -70% 01 Jan 2023 31 Dec 2023 10-K 31 Mar 2025 2024 FY
2022 $5,344,000 -$620,000 -10% 01 Jan 2022 31 Dec 2022 10-K 26 Mar 2024 2023 FY
2021 $5,964,000 +$736,000 +14% 01 Jan 2021 31 Dec 2021 10-K 22 Mar 2023 2022 FY
2020 $5,228,000 01 Jan 2020 31 Dec 2020 10-K 17 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.